4.7 Article

Mild cognitive impairment in Parkinson disease A multicenter pooled analysis

Journal

NEUROLOGY
Volume 75, Issue 12, Pages 1062-1069

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181f39d0e

Keywords

-

Funding

  1. Merck Serono
  2. Lundbeck Inc.
  3. Novartis
  4. GE Healthcare
  5. GlaxoSmithKline
  6. Solvay Pharmaceuticals, Inc
  7. Parkinson's Disease Society
  8. Patrick Berthoud Trust
  9. Boehringer Ingelheim
  10. ACADIA Pharmaceuticals
  11. Osmotica Pharmaceutical Corp.
  12. BrainCells Inc.
  13. Sanofi-Aventis
  14. Johnson Johnson
  15. Solvay Pharmaceuticals, Inc.
  16. NIH [NIMH K23 MH067894, NINDS P50 NS053488-01, NIA RO1AG031348, NINDS R01NS065087, NS36630, 1UL1 RR024156-01, PO412196-G]
  17. Michael J. Fox Foundation for Parkinson's Research
  18. University of Pennsylvania
  19. Amarin Corporation
  20. Boehringer Ingelheim NeuroSearch
  21. Parkinson Disease Foundation
  22. Huntington's Disease Society of America
  23. Parkinson Study Group
  24. Instituto de Salud Carlos III, Spain
  25. Wellcome Trust
  26. NIHR Health Technology Assessment Programme
  27. Michael J Fox Foundation
  28. UCB
  29. MDS Nordion
  30. Orion Corporation
  31. Brain Research Trust
  32. Parkinson's Appeal
  33. Western Norway Health Trust
  34. Norwegian Research Counsel
  35. Norwegian Parkinson's disease Association
  36. Neuroscience at a Glance (Blackwell Publishing)
  37. UK Medical Research Council
  38. NIHR
  39. Parkinson Hastalydy (Gunes Tip Kitapevi)
  40. Dementia in Parkinson's Disease (Oxford University Press)
  41. Eli Lilly and Company
  42. MRC [G0800784] Funding Source: UKRI
  43. Medical Research Council [G0800784, G0800784B] Funding Source: researchfish

Ask authors/readers for more resources

Background: In studies of mild cognitive impairment (MCI) in Parkinson disease (PD), patients without dementia have reported variable prevalences and profiles of MCI, likely to be due to methodologic differences between the studies. Objective: The objective of this study was to determine frequency and the profile of MCI in a large, multicenter cohort of well-defined patients with PD using a standardized analytic method and a common definition of MCI. Methods: A total of 1,346 patients with PD from 8 different cohorts were included. Standardized analysis of verbal memory, visuospatial, and attentional/executive abilities was performed. Subjects were classified as having MCI if their age-and education-corrected z score on one or more cognitive domains was at least 1.5 standard deviations below the mean of either control subjects or normative data. Results: A total of 25.8% of subjects (95% confidence interval [CI] 23.5-28.2) were classified as having MCI. Memory impairment was most common (13.3%; 11.6-15.3), followed by visuospatial (11.0%; 9.4-13.0) and attention/executive ability impairment (10.1%; 8.6-11.9). Regarding cognitive profiles, 11.3% (9.7-13.1) were classified as nonamnestic single-domain MCI, 8.9% (7.0-9.9) as amnestic single-domain, 4.8% (3.8-6.1) as amnestic multiple-domain, and 1.3% (0.9-2.1) as nonamnestic multiple-domain MCI. Having MCI was associated with older age at assessment and at disease onset, male gender, depression, more severe motor symptoms, and advanced disease stage. Conclusions: MCI is common in patients with PD without dementia, affecting a range of cognitive domains, including memory, visual-spatial, and attention/executive abilities. Future studies of patients with PD with MCI need to determine risk factors for ongoing cognitive decline and assess interventions at a predementia stage. Neurology (R) 2010;75:1062-1069

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available